How are Biosimilars influencing the Biologics Market?

Biosimilar Therapy Generic Market Analysis Report

Our latest offering, Global and USA Biosimilar Market Analysis provides a comprehensive analysis of both the biosimilar market and the biologics market. It looks at both markets in relation to each other and in that respect reveals trends and deals that companies are currently making. The report gives an analysis of the five major classes of originator biologics (TNF-a, EPO, Insulins, G-CSF, MAbs) and their market performance. It also looks at the dominance of biologics within the top ten drugs in the US economy. Within the EU, we analyse the top eight biologics in the market and also assess the following:

  • Global Market for Biologics
  • The Average Cost of Treatment with Biologic Drugs
  • Projected Global Market for Top-Selling Biologics
  • Projected Sales of Top-Selling Biologics in the U.S. Market
  • Comparison of Treatment Costs of Biologics and Non-Biologics
  • Projected Market for Biologics by Geography
  • Global Market for Biologics: Sales and Growth Rate for the Past Six Years
  • Top-Selling Biologics by Class
  • Five Biologics Least Affected by Biosimilars

We look at the following Biologics that are currently the focus of Biosimilar Developers

  • Aranesp (Darbepoietin alfa)
  • Enbrel
  • Epogen/Procrit/Eprex/Erypo
  • Genotropin
  • Herceptin
  • Humira
  • Neulasta
  • Neupogen
  • Remicade
  • Rituxan

Importantly, the report analyses the price differentials between branded Neupogen, Eprex, Genotropin and their biosimilar counterparts in Europe. It also looks at the impact of biosimilars on the following originator biologics:

  • Epogen
  • Humira
  • Remicade
  • Neupogen
  • Neulasta
  • Enbrel
  • Rituxan
  • Herceptin
  • Avastin
  • Lantus

The global market for biosimilars is analysed by drug class, geography and performance.  The biosimilar market leaders are identified and examined and the distribution of biosimilar companies by geography is also given. The report examines a number of specific factors influencing the market at present including the loss of patent protection for biologics and the market potential for biosimilars in the US.

The report takes an in-depth look at all the biosimilars on the market in Europe, the largest market globally, including:

  • Abasaglar
  • Abseamed
  • Accofil
  • Bemfola
  • Binocrit
  • Biograstim
  • Epoetin Alfa Hexal
  • Filgrastim Hexal
  • Grastofil
  • Inflectra
  • Nivestim
  • Omnitrope
  • Ovaleap
  • Ratiograstim
  • Remsima
  • Retacrit
  • Silapo
  • Tevagrastim
  • Zarzio

For ordering information, contact Deirdre on email